Literature DB >> 26847353

Hepatectomy After Yttrium-90 (Y90) Radioembolization-Induced Liver Fibrosis.

Ajay V Maker1,2,3, Carey August4, Vijay K Maker5,6, Elliot Weisenberg4.   

Abstract

An obese 55-year-old woman with nonalcoholic fatty liver disease presented 7 years after resection of a T3N1 ileal carcinoid tumor with an elevated chromogranin A, multifocal metastatic disease to the liver, and carcinoid syndrome. She underwent right hepatic artery yttrium-90 (Y90) radioembolization, followed a month later by selective Y90 treatment to segment IV. She then presented to our clinic 10 months later, remaining symptomatic with flushing, diarrhea, anxiety, myalgia, pain, and persistent night sweats despite Sandostatin administration. At least 11 tumors were identified in the right lobe of the liver and three in segment IV on liver-specific imaging. These lesions were stable over a year with no new lesions. At exploration, there was marked hypertrophy of the left lateral segment due to the yttrium-90 treatment of segments IV-VIII, corresponding with preoperative volumetrics predicting a functional liver remnant (FLR) of 40% after extended right hepatectomy. The right lobe and segment IV were fibrotic, hard, and visibly damaged. The gland had a thick, fibrotic capsule, and the parenchyma was dense, inflexible, and difficult to dissect, consistent with the previously reported morbidity of these operations. Extended right hepatectomy was performed. Final pathology demonstrated 15 foci of metastatic well-differentiated neuroendocrine carcinoma that were negative for necrosis, as was expected given her continued symptoms despite radioembolization. Numerous amorphous spheres, frequently in clusters, were present in segments IV-VIII in vessels and approximating tumors consistent with prior Y90 radioembolization. The patient had an uneventful post-operative recovery and remains symptom free on follow-up. Treatment options for metastatic tumors to the liver have increased in recent years and currently include radioembolization in selected patients. Surgical cytoreduction and complete metastasectomy continue to offer improvement in symptoms, quality of life, and survival in patients with neuroendocrine liver metastases; however, hepatectomy after radioembolization is unique and carries increased morbidity/mortality, likely due to Y90-induced liver fibrosis. We demonstrate images of fibrotic yttrium-90 radiation-affected liver and histological sections of radioembolic microbeads in blood vessels and distributed around resected tumors.

Entities:  

Keywords:  Bead embolization; Fibrosis; Hepatectomy; Liver metastases; Radioembolization; Y90

Mesh:

Substances:

Year:  2016        PMID: 26847353      PMCID: PMC4803592          DOI: 10.1007/s11605-016-3077-3

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  3 in total

Review 1.  A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90.

Authors:  Jin-Yao Teo; John C Allen; David C Ng; Su-Pin Choo; David W M Tai; Jason P E Chang; Foong-Khoon Cheah; Pierce K H Chow; Brian K P Goh
Journal:  HPB (Oxford)       Date:  2015-10-16       Impact factor: 3.647

2.  Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?

Authors:  Jessica E Maxwell; Scott K Sherman; Thomas M O'Dorisio; Andrew M Bellizzi; James R Howe
Journal:  Surgery       Date:  2015-10-09       Impact factor: 3.982

3.  Liver resection for metastatic disease after y90 radioembolization: a case series with long-term follow-up.

Authors:  Leonard R Henry; Richard B Hostetter; Brittany Ressler; Ingrid Bowser; Min Yan; Houman Vaghefi; John Abad; Seza Gulec; Roderich E Schwarz
Journal:  Ann Surg Oncol       Date:  2014-09-05       Impact factor: 5.344

  3 in total
  3 in total

Review 1.  Carcinoid-syndrome: recent advances, current status and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2018-02       Impact factor: 3.243

Review 2.  Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm.

Authors:  D Rohan Jeyarajah; Maria B Majella Doyle; N Joseph Espat; Paul D Hansen; David A Iannitti; Joseph Kim; Thavam Thambi-Pillai; Brendan C Visser
Journal:  J Gastrointest Oncol       Date:  2020-04

3.  Outcomes and toxicity following Yttrium-90 radioembolization for hepatic metastases from neuroendocrine tumors-a single-institution experience.

Authors:  Darryl A Zuckerman; Richard F Kennard; Amit Roy; Parag J Parikh; Ashley A Weiner
Journal:  J Gastrointest Oncol       Date:  2019-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.